A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with ...
Homozygous but not heterozygous loss of Pten in sporadic mouse models of SHH-medulloblastoma greatly accelerates tumor formation, not metastasis, through increased survival of differentiated cells and ...
PTEN is a tumor suppressor protein with potential therapeutic applications in cancer treatment. The research aims to explore the efficacy of CNTs as a delivery system for PTEN variants and assess ...
A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results